Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum probiotic blend
- Development stage
- Unknown
- Lead developer
- Shuangqi Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A probiotic formulation, specifically the Bifidobacterium Tetravaccine manufactured by Neimengu Shuangqi Pharmaceutical, containing live *Bifidobacterium longum* along with other beneficial bacteria such as *Lactobacillus acidophilus*, *Enterococcus faecalis*, and *Bacillus cereus*. It is utilized to modulate the gut microbiota, particularly in the context of postoperative recovery. In clinical studies conducted by the Third Affiliated Hospital of Sun Yat-Sen University, the blend is administered to pregnant women before and after Cesarean section to accelerate gastrointestinal recovery (e.g., reducing time to first flatus and defecation) and restore microbial balance disrupted by surgery and perioperative antibiotics.
- Brand names
- Si Lian Kang
- Other names
- Probiotic Blend Oral TabletBifidobacterium TetravaccineBifid-TetravaccineBifidobacterium longum combination
Beyond the preview
Go deeper on Bifidobacterium longum probiotic blend.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium longum probiotic blend.